Antiviral activity in vitro of Kutapressin against human herpesvirus-6.
The recently discovered human herpesvirus-6 (HHV-6) is being associated with an increasing number of conditions in which there is evidence of immunologic dysfunction. A number of widely available antiviral agents have shown little or no activity against the virus. We found that Kutapressin (KU), a drug that has been available to practicing physicians for over 50 years, has potent, previously unexpected antiviral effects. Cells known to allow replication of HHV-6 were infected with the virus, under various conditions. Either pretreatment of the cells prior to infection or treatment shortly after infection, inhibited viral replication by > 90%. Indirect evidence suggests that KU may inhibit viral attachment to cellular receptors, and inhibit intracellular maturation of the virus. Given these in vitro findings, and the low frequency of toxicity reported with the use of KU, clinical trials of this drug in patients with evidence of reactivated HHV-6 infection would seem to be warranted.
Ablashi
D V
DV
National Cancer Institute, Bethesda, MD 20892.
Berneman
Z N
ZN
Lawyer
C
C
Kramarsky
B
B
Ferguson
D M
DM
Komaroff
A L
AL
D000818:Animals; D023181:Antimicrobial Cationic Peptides; D000998:Antiviral Agents / Q000627:therapeutic use; D002460:Cell Line; D015654:Herpesvirus 6, Human / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008110:Liver Extracts / Q000494:pharmacology*; D010455:Peptides / Q000494:pharmacology*; D013552:Swine; D013601:T-Lymphocytes / Q000821:virology; D014779:Virus Replication / Q000187:drug effects
D023181:Antimicrobial Cationic Peptides; D000998:Antiviral Agents; D008110:Liver Extracts; D010455:Peptides; C092698:kutapressin